HSCT FOR SOLID TUMORS

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Symposium on Solid Tumors

Malignant melanoma Is an a^resslve, therapy-resistant malignancy of melanocytes. The incidence of meianoma has l>een steadily increasing worldwide, resulting In an increasing pubiic health problem. Exposure to solar UV radiation, fair skin, dysplastlc nevi syndrome, and a family history of meianoma are major risk factors for melanoma development. The interactions between genetic and environment...

متن کامل

Solid Tumors: a Review

The therapeutics of tumor is largely confined upon directly encountering the tumor cells. The current cytostatic agents mainly interfere with processes involved in cell growth while the aim in immunotherapy is to make immune effector cells to selectively attack the tumor cells. A recent approach to fight tumor is to impede and interfere with its blood supply, i.e., turning off angiogenesis or n...

متن کامل

Proton Radiotherapy for Solid Tumors of Childhood

The increasing efficacy of pediatric cancer therapy over the past four decades has produced many long-term survivors that now struggle with serious treatment related morbidities affecting their quality of life. Radiation therapy is responsible for a significant proportion of these late effects, but a relatively new and emerging modality, proton radiotherapy hold great promise to drastically red...

متن کامل

Nonmyeloablative allogeneic immunotherapy for solid tumors.

Over the past decade, considerable advances have been made in the field of allogeneic hematopoietic stem cell transplantation. Recognition that transplanted donor immune cells can cure patients with leukemia has led to the development of nonmyeloablative or "low-intensity" conditioning regimens, which have expanded the application of allogeneic transplantation to a growing number of hematologic...

متن کامل

Emerging trends for radioimmunotherapy in solid tumors.

Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: JBMTCT

سال: 2021

ISSN: 2675-374X

DOI: 10.46765/2675-374x.2021v4n1p131-137